PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 146 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2017. The put-call ratio across all filers is 1.47 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $413,000 | +103.4% | 55,300 | +61.7% | 0.01% | +150.0% |
| Q4 2017 | $203,000 | -25.4% | 34,200 | -7.3% | 0.00% | -33.3% |
| Q3 2017 | $272,000 | -11.1% | 36,900 | -18.2% | 0.00% | -25.0% |
| Q2 2017 | $306,000 | +18.1% | 45,100 | +64.6% | 0.00% | +33.3% |
| Q1 2017 | $259,000 | +488.6% | 27,400 | +163.5% | 0.00% | +200.0% |
| Q2 2016 | $44,000 | -84.9% | 10,400 | -78.2% | 0.00% | -75.0% |
| Q4 2015 | $292,000 | +87.2% | 47,600 | +74.4% | 0.00% | +100.0% |
| Q3 2015 | $156,000 | – | 27,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 17,902,338 | $135,342,000 | 5.88% |
| TIGER MANAGEMENT L.L.C. | 1,288,454 | $9,741,000 | 1.91% |
| Phocas Financial Corp. | 1,047,181 | $7,917,000 | 0.69% |
| TUDOR INVESTMENT CORP ET AL | 2,370,503 | $17,921,000 | 0.62% |
| EAM Investors, LLC | 553,309 | $4,183,000 | 0.58% |
| Baker Brothers Advisors | 4,449,797 | $33,640,000 | 0.34% |
| TFS CAPITAL LLC | 463,740 | $3,506,000 | 0.33% |
| FEDERATED HERMES, INC. | 13,508,290 | $102,123,000 | 0.32% |
| Rotella Capital Management, Inc. | 36,473 | $276,000 | 0.24% |
| OXFORD ASSET MANAGEMENT LLP | 1,103,848 | $8,351,000 | 0.18% |